Long-Term Safety of Pirtobrutinib for Leukemia and Lymphoma
This study is looking at the long-term safety of pirtobrutinib, a medication taken by mouth, for people with Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. You can join this study if you have already been part of another Lilly-sponsored study testing pirtobrutinib. The main goal is to track the percentage of participants who experience serious side effects (Grade 3 or higher) from the treatment. This study is designed to follow people who have completed earlier studies to understand the long-term effects of pirtobrutinib. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 787 participants. It is a 'master protocol' that allows people from previous studies to continue receiving treatment or follow-up.
- What's involved
- Participants will continue to receive treatment with pirtobrutinib or have follow-up visits after completing an earlier study. The study measures side effects from the first dose until 30 days (plus a 7-day window) after the last dose or starting new anticancer therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for side effects from the first dose of pirtobrutinib through 30 days (plus a 7-day window) after the last dose or the start of a new anticancer therapy, whichever comes first.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
At a glance
Conditions
Where it's being run
38 sites across 21 statesStudy leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Percentage of Participants with a Grade ≥3 treatment-emergent AEsTime from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier